Europe’s pharmaceutical industry faces mounting challenges as aggressive U.S. trade policies and China’s rapid biotech advancements threaten its historical dominance. Once the leader in global drug research and development, Europe now sees its share plummet from nearly half in 1990 to just 26% today. The U.S. is leveraging policies like most-favored-nation pricing to negotiate better drug prices, while China has emerged as a biotech powerhouse, attracting investments and innovation that were once the province of Europe.
This shift is critical for market professionals to understand, as it impacts investment strategies and the future of drug launches. European firms are increasingly reconsidering where to allocate resources, with many delaying or forgoing launches in Europe due to unfavorable pricing dynamics. The U.S. remains the most lucrative market, but the pressure from U.S. tariffs and regulatory hurdles in Europe could lead to a significant reallocation of investments.
For investors, the key takeaway is that Europe’s pharmaceutical landscape is at a crossroads. Without substantial reforms to improve competitiveness and investment attraction, the continent risks losing its status as a global leader in life sciences, potentially impacting stock performance and sector growth.
Source: cnbc.com